PDF herunterladen
Psychiatr Prax 2006; 33: 18-26
DOI: 10.1055/s-2005-867020
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Olanzapin in der Behandlung bipolarer affektiver Erkrankungen

Olanzapine in the Treatment of Bipolar DisorderStephanie  Krüger1
  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl-Gustav Carus, Dresden
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. März 2006 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Olanzapin ist ein atypisches Antipsychotikum, das sowohl zur Therapie der akuten Manie als auch zur Phasenprophylaxe der bipolaren Erkrankung zugelassen ist. Es gibt mittlerweile acht doppelblinde, plazebokontrollierte Studien, die die Wirksamkeit der Substanz in der Therapie der akuten Manien und fünf, die sie im Rückfallschutz belegen. Eine doppelblinde, plazebokontrollierte Studie untersuchte die Wirksamkeit von Olanzapin bei der bipolaren Depression. Olanzapin ist dabei mindestens genauso gut wirksam wie klassische stimmungsstabilisierende Substanzen, in einigen Studien ist es diesen sogar überlegen. Im folgenden Beitrag werden die einzelnen Studien zu den genannten Indikationsgebieten vorgestellt und kritisch diskutiert. Dabei wird auch auf Aspekte der Lebensqualität unter Olanzapintherapie und das Sicherheitsprofil der Substanz eingegangen.

Abstract

Olanzapin is an atypical antipsychotic drug, which is approved for use in acute mania and in the prophylaxis of bipolar disorder. There are eight double-blind, placebo-controlled studies, which show its efficacy in the treatment of acute mania, five, which document its efficacy in the long-term treatment of bipolar disorder and one that shows its use in bipolar depression. The following overview presents and critically evaluates these studies. Quality of life aspects on olanzapine treatment and the safety profile of the drug will also be discussed.

Literatur

  • 1 Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics.  J Clin Psychiatry. 1996;  57, Suppl 11 12-25
    PubMedGoogle Scholar
  • 2 Fulton B, Goa K L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.  Drugs. 1997;  53 (2) 281-298
    CrossrefPubMedGoogle Scholar
  • 3 Callaghan J T, Bergstrom R F, Ptak L R, Beasley C M. Olanzapine. Pharmacokinetic and pharmacodynamic profile.  Clin Pharmacokinet. 1999;  37 (3) 177-193
    CrossrefPubMedGoogle Scholar
  • 4 Kassahun K, Mattiuz E, Nyhart Jr E, Obermeyer B, Gillespie T, Murphy A. et al . Disposition and biotransformation of the antipsychotic agent olanzapine in humans.  Drug Metab Dispos. 1997;  25 (1) 81-93
    PubMedGoogle Scholar
  • 5 Weigmann H, Hartter S, Maehrlein S, Kiefer W, Kramer G, Dannhardt G. et al . Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.  J Chromatogr B Biomed Sci Appl. 2001;  759 (1) 63-71
    CrossrefPubMedGoogle Scholar
  • 6 Chiu J A, Franklin R B. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection.  J Pharm Biomed Anal. 1996;  14 (5) 609-615
    CrossrefPubMedGoogle Scholar
  • 7 Bymaster F P, Hemrick-Luecke S K, Perry K W, Fuller R W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.  Psychopharmacology (Berl). 1996;  124 (1 - 2) 87-94
    PubMedGoogle Scholar
  • 8 Schlicker E, Marr I. The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics.  Naunyn Schmiedebergs Arch Pharmacol. 1996;  353 (3) 290-294
    CrossrefPubMedGoogle Scholar
  • 9 Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2nd ed. Bremen; Uni-Med Science 2000
    Google Scholar
  • 10 Stephenson C M, Pilowsky L S. Psychopharmacology of olanzapine. A review.  Br J Psychiatry Suppl. 1999;  (38) 52-58
    PubMedGoogle Scholar
  • 11 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G. et al . Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.  Arch Gen Psychiatry. 2000;  57 (9) 841-849
    CrossrefPubMedGoogle Scholar
  • 12 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G. et al . Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156 (5) 702-709
    PubMedGoogle Scholar
  • 13 Tohen M, Baker R W, Altshuler L L, Zarate C A, Suppes T, Ketter T A. et al . Olanzapine versus divalproex in the treatment of acute mania.  Am J Psychiatry. 2002;  159 (6) 1011-1017
    CrossrefPubMedGoogle Scholar
  • 14 Zajecka J M, Weisler R, Sachs G, Swann A C, Wozniak P, Sommerville K W. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.  J Clin Psychiatry. 2002;  63 (12) 1148-1155
    CrossrefPubMedGoogle Scholar
  • 15 Tohen M, Chengappa K N, Suppes T, Zarate Jr C A, Calabrese J R, Bowden C L. et al . Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.  Arch Gen Psychiatry. 2002;  59 (1) 62-69
    CrossrefPubMedGoogle Scholar
  • 16 Tohen M, Goldberg J F, Gonzalez-Pinto Arrillaga A M, Azorin J M, Vieta E, Hardy-Bayle M C. et al . A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.  Arch Gen Psychiatry. 2003;  60 (12) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 17 Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J. et al . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.  J Clin Psychopharmacol. 2001;  21 (4) 389-397
    CrossrefPubMedGoogle Scholar
  • 18 Goodwin F K, Jamison K R. Manic-depressive illness. New York; Oxford University Press 1990
    Google Scholar
  • 19 Himmelhoch J M, Garfinkel M E. Mixed mania, diagnosis and treatment: sources of lithium resistance.  Psychopharmacology Bulletin. 1986;  22 613-620
    PubMedGoogle Scholar
  • 20 Himmelhoch J M, Mulla D, Neil J F, Detre T P, Kupfer D J. Incidence and significance of mixed affective states in a bipolar population.  Arch Gen Psychiatry. 1976;  33 (9) 1062-1066
    CrossrefPubMedGoogle Scholar
  • 21 World Health Organization .Internationale Klassifikation psychischer Störungen, ICD 10. Bern, Switzerland; Hans Huber 1994
    Google Scholar
  • 22 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC; American Psychiatric Press 1996
    Google Scholar
  • 23 Bräunig P. Diagnose, Verlauf und Ausgang zykloider Psychosen. Habilitationsschrift, Band I ed. 1992
    Google Scholar
  • 24 Boland R J, Keller M B. Mixed-State bipolar disorders: outcome data from the NIMH Collaborative Program on the Psychobiology of Depression. In: Goldberg JF, Harrow JM (eds) Bipolar disorders: clinical course and outcome. Washington DC; American Psychiatric Press 1999: 115-128
    Google Scholar
  • 25 Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L. Association of recurrent suicidal ideation with non-remission from acute mixed mania.  Am J Psychiat. 1998;  155 (12) 1753-1755
    PubMedGoogle Scholar
  • 26 Goldberg J F, Garno J, Portera L, Leon A C, Kocsis J H, Whiteside H L. Correlates of suicidal ideation in dysphoric mania.  J Affect Disord. 1999;  56 (1) 75-81
    CrossrefPubMedGoogle Scholar
  • 27 Krüger S, Cooke R G, Spegg C, Bräunig P. Relevance of the catatonic syndrome to the mixed manic episode.  Journal of Affective Disorder. 2003;  74 (3) 279-285
    CrossrefPubMedGoogle Scholar
  • 28 Himmelhoch J M, Garfinkel M E. Sources of lithium resistance in mixed mania.  Psychopharmacol Bull. 1986;  22 (3) 613-620
    PubMedGoogle Scholar
  • 29 Tohen M, Vieta E, Calabrese J, Ketter T A, Sachs G, Bowden C. et al . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.  Arch Gen Psychiatry. 2003;  60 (11) 1079-1088
    CrossrefPubMedGoogle Scholar
  • 30 Tohen M, Ketter T A, Zarate C A, Suppes T, Frye M, Altshuler L. et al . Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.  Am J Psychiatry. 2003;  160 (7) 1263-1271
    CrossrefPubMedGoogle Scholar
  • 31 Baker R W, Tohen M, Fawcett J, Risser R C, Schuh L M, Brown E. et al . Acute dysphoric mania: treatment response to olanzapine versus placebo.  J Clin Psychopharmacol. 2003;  23 (2) 132-137
    CrossrefPubMedGoogle Scholar
  • 32 Dennehy E B, Doyle K, Suppes T. The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting.  Int Clin Psychopharmacol. 2003;  18 (3) 143-145
    PubMedGoogle Scholar
  • 33 Ketter T A, Winsberg M E, DeGolia S G, Dunai M, Tate D L, Strong C M. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states [letter] [see comments].  J Clin Psychiatry. 1998;  59 (2) 83-85
    PubMedGoogle Scholar
  • 34 Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine.  J Psychiatry Neurosci. 1999;  24 (1) 40-44
    PubMedGoogle Scholar
  • 35 Baldassano C F, Ballas C A, O'Reardon J P. Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.  CNS Spectr. 2004;  9 (9 Suppl 9) 11-18
    PubMedGoogle Scholar
  • 36 Hirschfeld R M. Bipolar depression: the real challenge.  Eur Neuropsychopharmacol. 2004;  14, Suppl 2 S83-S88
    CrossrefPubMedGoogle Scholar
  • 37 Gijsman H J, Geddes J R, Rendell J M, Nolen W A, Goodwin G M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.  Am J Psychiatry. 2004;  161 (9) 1537-1547
    CrossrefPubMedGoogle Scholar
  • 38 Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F. et al . Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.  J Clin Psychopharmacol. 2001;  21 (5) 469-473
    CrossrefPubMedGoogle Scholar
  • 39 Sanger T M, Grundy S L, Gibson P J, Namjoshi M A, Greaney M G, Tohen M F. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.  J Clin Psychiatry. 2001;  62 (4) 273-281
    PubMedGoogle Scholar
  • 40 Tohen M, Chengappa K N, Suppes T, Baker R W, Zarate C A, Bowden C L. et al . Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.  Br J Psychiatry. 2004;  184 337-345
    CrossrefPubMedGoogle Scholar
  • 41 Barrios C, Chaudhry T A, Goodnick P J. Rapid cycling bipolar disorder.  Expert Opin Pharmacother. 2001;  2 (12) 1963-1973
    CrossrefPubMedGoogle Scholar
  • 42 Calabrese J R, Shelton M D, Rapport D J, Kujawa M, Kimmel S E, Caban S. Current research on rapid cycling bipolar disorder and its treatment.  J Affect Disord. 2001;  67 (1 - 3) 241-255
    CrossrefPubMedGoogle Scholar
  • 43 Sanger T M, Tohen M, Vieta E, Dunner D L, Bowden C L, Calabrese J R. et al . Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.  J Affect Disord. 2003;  73 (1 - 2) 155-161
    CrossrefPubMedGoogle Scholar
  • 44 Meyer C, Rumpf H J, Hapke U, John U. Impact of psychiatric disorders in the general population: satisfaction with life and the influence of comorbidity and disorder duration.  Soc Psychiatry Psychiatr Epidemiol. 2004;  39 (6) 435-441
    PubMedGoogle Scholar
  • 45 Perlis R H, Miyahara S, Marangell L B, Wisniewski S R, Ostacher M, DelBello M P. et al . Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD).  Biol Psychiatry. 2004;  55 (9) 875-881
    CrossrefPubMedGoogle Scholar
  • 46 Dean B B, Gerner D, Gerner R H. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder.  Curr Med Res Opin. 2004;  20 (2) 139-154
    PubMedGoogle Scholar
  • 47 Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M. et al . Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome.  Bipolar Disord. 2004;  6 (3) 224-232
    CrossrefPubMedGoogle Scholar
  • 48 Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J. et al . Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.  Am J Psychiatry. 2004;  161 (2) 262-270
    CrossrefPubMedGoogle Scholar
  • 49 Shi L, Namjoshi M A, Swindle R, Yu X, Risser R, Baker R W. et al . Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.  Clin Ther. 2004;  26 (1) 125-134
    CrossrefPubMedGoogle Scholar
  • 50 Shi L, Namjoshi M A, Zhang F, Gandhi G, Edgell E T, Tohen M. et al . Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.  Int Clin Psychopharmacol. 2002;  17 (5) 227-237
    PubMedGoogle Scholar
  • 51 Namjoshi M A, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.  J Affect Disord. 2004;  81 (3) 223-229
    CrossrefPubMedGoogle Scholar
  • 52 Namjoshi M A, Rajamannar G, Jacobs T, Sanger T M, Risser R, Tohen M F. et al . Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.  J Affect Disord. 2002;  69 (1 - 3) 109-118
    CrossrefPubMedGoogle Scholar
  • 53 Haberfellner E M, Rittmannsberger H. Weight gain during long-term treatment with olanzapine: a case series.  Int Clin Psychopharmacol. 2004;  19 (4) 251-253
    PubMedGoogle Scholar
  • 54 Liberty I F, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association.  Isr Med Assoc J. 2004;  6 (5) 276-279
    PubMedGoogle Scholar
  • 55 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus Development Conference in antipsychotic drugs an obesity and diabetes.  Diabetes Care. 2004;  27 596-601
    CrossrefPubMedGoogle Scholar
  • 56 Vieta E, Sanchez-Moreno J, Goikolea J M, Colom F, Martinez-Aran A, Benabarre A. et al . Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.  J Clin Psychopharmacol. 2004;  24 (4) 374-378
    PubMedGoogle Scholar
  • 57 Kanner A M, Wuu J, Faught E, Tatum W O, Fix A, French J A. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.  Epilepsy Behav. 2003;  4 (5) 548-552
    CrossrefPubMedGoogle Scholar
  • 58 Meador K J, Loring D W, Hulihan J F, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate.  Neurology. 2003;  60 (9) 1483-1488
    CrossrefPubMedGoogle Scholar

PD Dr. med. Stephanie Krüger

Klinik und Poliklinik für Psychiatrie und Psychotherapie · Universitätsklinikum Carl-Gustav Carus

Fetscherstraße 74

01307 Dresden

eMail: stephanie.krueger@uniklinikum-dresden.de